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Infection of Human Papillomavirus Type
18 and p53 Codon 72 Polymorphism in
Lung Cancer Patients From India*
Neeraj Jain, PhD; Vikram Singh, MD; Suresh Hedau, PhD; Suresh Kumar, MD;
Mradul K. Daga, MD; Richa Dewan, MD; Nandagudi S. Murthy, PhD;
Syed A. Husain, PhD; and Bhudev C. Das, PhD
Study objectives: Infection with specific high-risk HPV types 16 and 18 and polymorphism of p53
codon 72 has been strongly associated with the genesis of various neoplasms in humans, but such
study in lung cancer is limited and the results are controversial. In India, the role of these two
factors has been strongly implicated in cervical and other cancers, but the occurrence of HPV or
p53 codon 72 polymorphism has not been examined in lung cancer, which is the most common
cause of cancer-related death in India.
Design and patients: A total of 40 tumor biopsy specimens from advanced lung cancer patients
and blood samples from 40 matching control subjects were obtained for the analysis of high-risk
HPV types 16 and 18 infection and p53 codon 72 polymorphism by polymerase chain reaction.
Results: Only HPV type 18 was detected in 5% (2 of 40 lung cancer patients), but no other HPV
could be detected. A significantly increased frequency of Arg/Arg homozygotes was observed in
patients with advanced lung cancer when compared to that of control subjects (p  0.004; odds
ratio, 5.13; 95% confidence interval, 1.59 to 17.26). However, no significant correlation could be
made between p53 polymorphism and different clinical stages, except for advanced stage IV
patients, who showed a higher proportion of Arg/Pro heterozygous genotype.
Conclusions: HPV detected in a small proportion of lung cancer patients in India demonstrated
an exclusive prevalence of HPV type 18, and there was a significantly higher frequency of p53
Arg/Arg genotype when compared to that of control subjects. Observation of a shorter duration
of symptoms (< 4 months) in as many as 78% (seven of nine stage IV patients) with Arg/Pro
genotype may be an indication that lung cancer patients with the heterozygous p53 genotype are
more susceptible to early progression. (CHEST 2005; 128:3999–4007)
Key words: human papillomavirus; lung cancer; p53 codon 72 polymorphism; polymerase chain reaction
Abbreviations: bp  base-pair; CI confidence interval; HPV human papillomavirus; OR odds ratio;
PCR polymerase chain reaction
L ung cancer, which involves malignant prolifera-tion of the epithelial lining of the lower respira-
tory tract, is one of the most common form of
malignancy leading to the major cause of cancer-
related deaths around the world1 including India.2
Smoking is considered to be one of the principal
causes of lung cancer; however, not all smokers
acquire lung cancer, while many nonsmokers includ-
ing passive smokers do acquire lung cancer.3–5
Therefore, various other etiologic factors, including
genetic factors such as mutation or overexpression of
oncogenes such as c-myc, erbB2, K-ras, polymor-
phism in P450 (CYP1A1) and glutathione transferase
M1 genes, functional inactivation of tumor suppres-
sor genes eg, Rb, p16, p53 gene including p53 codon
72 polymorphism, and infection of specific types of
human papillomaviruses (HPVs), have been impli-
cated with the development of lung cancer.6–9
Infection with HPV has been associated with the
development of  10% of human cancers,10 includ-
ing cervical, oral, esophageal, laryngeal, and head
and neck cancer.11 Of the  100 types of HPVs
described so far, HPV types 16 and 18 are most
commonly associated with malignant lesions and are
impact of basic research on tomorrow’s
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referred to as “high-risk” types. The early oncopro-
tein E7 of high-risk HPVs binds to and inactivates
the cellular tumor suppressor protein Rb, while the
E6 protein binds to the p53 protein and directs its
ubiquitin-mediated proteolytic degradation and in-
terferes with the cell cycle control resulting in
abnormal cell proliferation and tumor growth.12–14
The reports on the involvement of HPV infection in
lung cancer are not only rare but also controversial.
Several authors15–18 have reported that HPV has no
role to play in lung carcinogenesis, whereas oth-
ers19–23 have observed a low frequency (4 to 18%) of
HPV infection in lung cancer. In contrast, a moder-
ate to a very high frequency of HPV infection (30 to
79%) has been reported by several other authors24–29
from different regions of the world. Observation of
such a wide variation in HPV prevalence in lung
cancer appears to be an indication of either geo-
graphic and/or ethnic variation or due to varied
protocols and primers/probes used by different lab-
oratories.
p53 protein, which exists in two polymorphic
forms (p53-Pro or p53-Arg) in the general popula-
tion due to single nucleotide change at codon 72 of
exon 4 of the p53 gene,30,31 shows different struc-
tural and functional properties.32 It has been shown
that the p53-Arg protein is more susceptible to
E6-mediated proteolytic degradation than p53-Pro
isoform, and women with homozygous p53 Arg/Arg
genotype are at least seven times higher risk of
acquiring HPV-induced cervical cancer.33 However,
conflicting results have been reported for cervical
and other cancers including lung cancer. While few
reports34–38 supported the above findings, many
others,39–47 including our previous study,48 also
failed to confirm the same. The association of p53
codon 72 polymorphism has been studied in lung
carcinoma by several authors,22,36,49–53 but the re-
sults are contradictory. While the frequency of Pro/
Pro genotype was reported to be higher in lung
cancer by some authors,49,50 Papadakis and group22
observed an increased frequency of Arg/Arg geno-
type in advanced lung cancer cases, but Tagawa et
al54 reported overrepresentation of this genotype in
nonsmoking lung cancer patients. Others51–53 have
observed no significant association between p53
codon 72 polymorphism and lung cancer. Further-
more, it has been demonstrated that patients with
Pro/Pro genotype had a worse prognosis when com-
pared to those with Arg/Pro genotype.36
In India, the prevalence of HPV in cervical cancer
is extremely high (approximately 98%), and HPV 16
is the high-risk type exclusively prevalent not only in
squamous cell carcinoma (approximately 90%)55 but
in adenocarcinoma of the uterine cervix56 as well as
in oral57 and esophageal cancer.58 However, no study
on the prevalence of HPV as well as p53 codon 72
polymorphism in lung cancer has been reported
from India. We report here an exclusive occurrence
of HPV 18 infection in lung cancer patients who
showed higher frequency of Arg/Arg homozygous
p53 genotype, but the patients showed an aggressive
progression if they harbor heterozygous Arg/Pro p53
genotype.
Materials and Methods
Tissue Specimens
A total of 40 incident lung cancer patients who reported to the
Department of Medicine, Lok Nayak Hospital, New Delhi
during the period 2003 to 2004 formed the study group. A
detailed history relating to demographic particulars, history of
smoking, tuberculosis, and family history of lung cancer or any
other cancer was collected in a pretested proforma. In addition,
clinical details regarding stage of the disease, histology, and
degree of anaplasia were obtained from the clinical records.
Tumor biopsy specimens were collected in ice-cold phosphate-
buffered saline solution from the surgical operation theater,
either during fiberoptic bronchoscopy or trucut needle biopsy
obtained under CT guidance from lung cancer patients after
obtaining their informed consent, and were stored at – 70°C in a
deep freezer until further analysis. Peripheral venous blood
samples from 40 healthy control subjects matched for age, sex,
and smoking habits were also collected for comparison. Control
subjects were unrelated to the patients and were attending the
outpatient department of medicine for ailments other than
cancer.
DNA Extraction, Polymerase Chain Reaction, and Detection of
HPV Infection
High-molecular-weight genomic DNA from biopsy and blood
samples was isolated by the standard method of proteinase K
digestion and phenol chloroform extraction routinely followed in
our laboratory.59 Detection of HPV was carried out first by using
consensus primers located within the conserved L1 region of
HPV genome resulting in amplimer of 450 base-pair (bp)60
(forward primer, 5-GCMCAGGGWCAT AAYAATGG-3, re-
verse primer, 5-CGTCCMARRGGAWACTGATC-3 where
M  A  C, W  A  T, Y  C  T, R  A  G) and later by
type-specific primers for high risk types 16 (amplimers size, 217
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bp) and 18 (amplimers size, 100 bp) [HPV 16 forward primer,
5-AAGGCCAACTAAATGTCAC-3, reverse primer, 5-CT-
GCTTTTATACTAACCGG-3; HPV 18 forward primer, 5-AC-
CTTAATG AAAAACCACGA-3, reverse primer, 5-CGTCGTT-
TAGAGTCGTTCCTG-3], as described earlier.55 Polymerase
chain reaction (PCR) was performed using the in-house PCR
protocol routinely followed in our laboratory.59 Briefly, the
method involved a 25-L reaction mix containing 100 to 200 ng
of DNA, 10 mmol/L of Tris Cl (pH 8.4), 50 mmol/L of KCl, 1.5
mmol/L of MgCl2, 12.5 mol/L of each deoxynucleoside triphos-
phate (deoxyadenosine triphosphate, deoxycytidine triphosphate,
deoxyguanosine triphosphate, and deoxythymidine triphosphate),
5 pmol of each oligonucleotide primer, and 0.5 U of Taq DNA
polymerase (Perkin-Elmer Biosystems; Foster City, CA). The
temperature profile used for amplification constituted an initial
denaturation at 95°C for 5 min followed by 30 cycles with
denaturation at 95°C for 30 s, annealing at 55°C for 30 s and
extension at 72°C for 30 s, which was extended for 4 min in the
final cycle. Amplification of -globin gene (forward primer,
5-GAAGAGCCAAGGACAGGTAC-3, reverse primer, 5-
CAACTT CATCCACGTTACACC-3) with an amplimer of 268
bp served as the internal control (Fig 1). The oligonucleotide
primers were synthesized in an automated DNA synthesizer
(Model 381A; Applied Biosystems; Foster City) and were puri-
fied with high-performance liquid chromatography.
Analysis of p53 Codon 72 Arg/Pro Polymorphism
The PCR amplification for the analysis p53 codon 72 arginine
and proline alleles was carried out in separate reactions using the
same set of primers as described by Storey et al33 (p53 Pro
 5-GCCAGAGGCTGCTCCCCC-3, p53- 5-CGTGCAAGT-
CACAGACTT-3 and p53 5-TCCCCCTTGCCGTCCCAA-3,
p53 Arg- 5-CTGGTGCAGGGGCCACGC-3). The procedure
was the same as followed for HPV PCR except a slight modifi-
cation of the temperature profile.48 The amplified products of
141 bp for p53Arg and 177 bp for p53 Pro were visualized (Fig 2)
on an ethidium bromide-stained 3% Nusieve agarose gel (FMC
Bioproducts; Rockland, ME) under an ultraviolet transillumina-
tor or a gel documentation system (BioRad Laboratories; Her-
cules, CA).
Statistical Analysis
Means and SD were calculated for quantitative data. 2 or
Fisher Exact Tests were employed to test for significance of
results.
Results
Of 40 lung cancer patients, 35 patients (87.5%)
were men and 5 patients (12.5%) were women
(mean SD age, 56.8 9.7 years and 62.2 11.2
years, respectively). Only six patients (15%) were
nonsmokers, while remaining were smokers; pack-
years ranged from 6 to 150. One pack-year corre-
sponds to a pack of 20 cigarettes smoked daily over a
period of 1 year. None of the patients had any family
history of lung cancer or any other cancer. His-
topathologic typing revealed 22 cases (55%) of squa-
mous cell carcinoma, 9 cases (22.5%) of adenocarci-
noma, 8 cases (20%) of small cell lung carcinoma,
and 1 case (2.5%) of large cell lung carcinoma.
HPV Status
HPV infection was first detected using L1 consen-
sus primers and then typed using specific primers for
high-risk HPV type 16 and HPV 18 in a total of 40
lung cancer cases. Only two cases (5%) showed HPV
positivity by consensus primers, which later revealed
presence of only HPV 18 DNA sequences by type-
specific primers (Table 1). None of the samples
showed presence of HPV type 16, which is the most
prevalent HPV type in anogenital, oral, and esopha-
geal cancer in India. Both the HPV 18-positive cases
Figure 1. PCR amplification of HPV 18 DNA sequences (100
bp) along with the -globin gene (268 bp) as an internal control
in DNA isolated from lung carcinoma tissue biopsy samples.
Lane 1 is Hae III-digested X174 DNA molecular weight
marker. Lane 2 is positive control (HPV 18 plasmid DNA). Lane
3 is negative control (placental DNA). Lanes 4 to 10 are tumor
samples. Lanes 4 and 7 represent positive samples for HPV 18.
Figure 2. PCR amplification of proline (top lanes) and arginine
(bottom lanes) alleles of codon 72 in exon 4 of the p53 gene
showing amplimer sizes of 177 bp for proline and 141 bp for
arginine. Lane 1: Hae III-digested X174 DNA molecular
weight marker; lanes 4 and 7 are proline homozygotes (Pro/Pro),
while lanes 3, 6, 8, and 9 are Arginine (Arg/Arg) homozygotes and
lanes 2, 5, and 10 are Arg/Pro heterozygotes.
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were moderately differentiated carcinomas and be-
longed to TNM stage IV, which showed heterozy-
gous p53 Arg/Pro genotypes. Since only two patients
had positive findings for HPV infection, no statistical
analysis could be performed either with different
clinicopathologic features or p53 codon 72 polymor-
phism. All the 40 control subjects were also sub-
jected for L1 consensus PCR to detect HPV infec-
tion if any, but none of them showed any HPV
amplification. All the tumor and control DNA sam-
ples showed good amplification of -globin gene,
which served as an internal control.
p53 Codon 72 Arg/Pro Polymorphism
The proportion of Arg/Arg or Pro/Pro homozygos-
ity and Arg/Pro heterozygosity in 40 lung cancer
cases was found to be 47.5%, 10.0%, and 42.5%,
respectively, as compared to 15.0%, 25.0%, and
60.0% in the control subjects (n 40). The differ-
ence in the proportion of subjects revealing Arg/Arg
homozygosity between the lung cancer patients and
normal control subjects was found to be statistically
significant (p 0.004; odds ratio [OR], 5.13; 95%
confidence interval [CI], 1.59 to 17.26). On compar-
ing the Pro/Pro and Arg/Pro genotypes between
cases and control subjects, the difference was not
found to be statistically significant (p 0.14 and
p  0.18, respectively) [Table 1].
Association of p53 Codon 72 Polymorphism With
Clinicopathologic Features
Statistically, no significant association could be
observed when a comparison was made between
different clinicopathologic profiles and the three
different p53 genotypes except for 9 of 15 stage IV
patients (60%) who exhibited a heterozygous Arg/
Pro genotype (Table 2). Interestingly, of these nine
patients, seven patients (77.8%) showed duration of
symptoms  4 months, which is a much shorter
period when compared to that of other stages. The
frequency of arginine homozygotes, however,
showed an increasing trend with the increasing age
and higher pack-years (Table 2).
Discussion
The reports on the prevalence of HPV infection in
lung carcinoma worldwide are limited as well as
conflicting, and the frequency ranges from zero to as
high as 80% (Table 3). We have observed a very low
frequency (5%) of HPV infection (HPV type 18
only), and no other HPV could be detected, includ-
ing HPV type 16, which is almost exclusively preva-
lent in cervical, oral, and esophageal cancer in
India.57–59 An exclusive occurrence of HPV 18 infec-
tion in lung cancer has also been reported by other
groups20,22,23 from different regions (Table 3). The
occurrence of specifically HPV type 18 in lung
cancer is intriguing. It is also interesting that al-
though the p53 Arg/Arg genotype is significantly
higher in advanced lung cancer patients, the two
HPV 18-positive cases that also belonged to ad-
vanced stage IV showed a heterozygous (Pro/Arg)
genotype.
A high degree of difference in the prevalence of
HPV infection in lung cancer around the globe has
long been attributed to geographic and ethnic vari-
ation, but surprisingly two reports18,27 on lung cancer
from the same location in Greece showed completely
opposite results. While Papadopoulou and col-
leagues27 demonstrated HPV positivity as high as
69%, Gorgoulis et al18 reported the complete ab-
sence of HPV infection in lung cancer. Similarly,
from Japan, HPV prevalence of 79% was reported by
two groups,28,29 but Miyagi et al26 reported only
34%. In addition, Szabo et al16 found the complete
absence of HPV infection in lung cancer. The above
reports as well as other studies (Table 3) do indicate
that there may be other factors responsible for
variation in HPV prevalence. As it is generally seen
in many cases of bacterial or viral infections, there
could be seasonal variation of HPV infection within
the same region and population. However, the major
variability in results may be attributed to different
methodologies, PCR protocols, sensitivity and spec-
ificity of these methods, and selection of patients
including host factors.22,29,61,62 The observation of a
very low frequency of HPV infection in lung cancer
Table 1—p53 Codon 72 Polymorphism and HPV Prevalence in Lung Cancer Patients and Control Subjects*
Groups
p53 Polymorphism HPV Status
Arg/Arg† Arg/Pro‡ Pro/Pro§ HPV 16 HPV 18
Lung cancer patients (n  40) 19 (47.5) 17 (42.5) 4 (10.0) 0 2 (5.0)
Control subjects (n  40) 6 (15.0) 24 (60.0) 10 (25.0) 0 0
*Data are presented as No. (%).
†p  0.004 (OR, 5.13; 95% CI, 1.59 to 17.26).
‡p  0.18.
§p  0.14.
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by us and several other authors20,63,64 does not
support its major role in lung carcinogenesis. How-
ever, it would be important to see the effect of HPV
alone in the absence of other associated carcinogenic
factors in lung cancer.
Several studies33,37,38 indicate a close relation be-
tween risk of cancer and p53 Arg homozygosity that
confers high susceptibility to the p53 protein for
degradation through HPV early protein E6-medi-
ated ubiquitin pathways, while others46,47 failed to
Table 3—Prevalence of HPV Infection in Lung Cancer: Worldwide Scenario*
Study
No.
Cases
Studied,
No. HPV 16 HPV18
HPV 16 and HPV 18
Co-infection Others†
Total HPV
Positivity Region Source/Year
1 33 1 (3.0) 3 (9.0) 1 (3.0) 2 (6.0) 6 (18.0) Lyon, France Bejui-Thivolet et al,19 1990
2 47 0 0 0 0 0 Kawaga, Japan Szabo et al,16 1994
3 50 10 (20.0) 5 (10.0) 1 (2.0) 0 16 (32.0) Wahan, China Qingquan et al,25 1995
4 43 5 (11.6) 5 (11.6) 13 (30.2) 11 (25.6)‡ 34 (79.0) Okinawa, Japan Hirayasu et al,29 1996
30 2 (6.6) 7 (23.3) 0 0 9 (30.0) Nigata, Japan
5 38 0 0 0 0 0 Berlin, Germany Welt et al,17 1997
6 34 0 2 (5.8) 0 0 2 (5.8) Colorado Bohlmeyer et al,20 1998
7 52 11 (21.0)§ 11 (21.0)§ 11 (21.0)§ 25 (48.0)§ 36 (69.0) Athens, Greece Papadopoulou et al,27 1998
8 23 5 (21.7) 4 (17.3) 3 (13) 6 (26)‡ 18 (78.0) Okinawa, Japan Tsuhako et al,28 1998
9 68 0 0 0 0 0 Athens, Greece Gorgoulis et al,18 1999
10 26 2 (7.7)§ 2 (7.7)§ 2 (7.7)§ 1 (3.8)§ 3 (11.5) Istanbul, Turkey Kaya et al,21 2001
11 121 15 (12.4) 19 (15.7) 0 7 (5.8) 41 (33.8) Okinawa, Japan Miyagi et al,26 2001
12 58 2 (3.4)§ 2 (3.4)§ 2 (3.4)§ 5 (8.6)§ 7 (12.0) Pennsylvania Yousem et al,24 1992
13 54 0 2 (3.7) 0 0 2 (3.7) Athens, Greece Papadakis et al,22 2002
14 40 0 2 (5.0) 0 0 2 (5.0) Ankara, Turkey Zafer et al 2004,23
15 40 0 2 (5.0) 0 0 2 (5.0) New Delhi, India This study
*Data are presented as No. (%) unless otherwise indicated.
†HPV 6, 11, 31, 33, 35, 52, and 58.
‡Others with HPV 16 and/or HPV 18 co-infection.
§Mixed probe used 6/11,16/18, 31/33/35.
Table 2—Frequency of p53 Genotypes and Clinicopathologic Features of Lung Cancer Patients
and Control Subjects*
Variables
p53 Polymorphism
Arg/Arg Arg/Pro Pro/Pro Total
Clinical features 19 (47.5) 17 (42.5) 4 (10.0) 40
Sex
Male 16 (45.7) 15 (42.8) 4 (11.4) 35
Female 3 (60.0) 2 (40.0) 0 5
Age at diagnosis, yr
 55 9 (42.8) 10 (47.6) 2 (9.5) 21
 55 10 (52.6) 7 (36.8) 2 (10.5) 19
Pack-years
0 4 (50.0) 3 (37.5) 1 (12.5) 8
 40 6 (46.1) 5 (38.4) 2 (15.3) 13
 40 9 (47.3) 9 (50.0) 1 (5.2) 19
Histologic type
Squamous cell carcinoma 11 (52.3) 9 (42.8) 1 (4.7) 21
Adenocarcinoma 3 (33.3) 4 (44.4) 2 (22.2) 9
Small cell carcinoma 4 (44.4) 4 (44.4) 1 (11.1) 9
Large cell carcinoma 1 (100.0) 0 0 1
Stage
IIB 2 (28.5) 4 (57.1) 1 (14.2) 7
IIIA 8 (57.1) 3 (21.4) 3 (21.4) 14
IIIB 3 (75.0) 1 (25.0) 0 4
IV 6 (40.0) 9 (60.0) 0 15
Control subjects 6 (15.0) 24 (60.0) 10 (25.0) 40
*Data are presented as No. (%).
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find such an association. Observations on the associ-
ation between p53 codon 72 polymorphism and lung
cancer have been inconsistent (Table 4). While
several studies51,53 found no association between p53
codon 72 polymorphism and lung cancer, other
authors36,49,50 reported an increased frequency of
Pro/Pro homozygotes in lung cancer. Studies36,50 of
Asian and Mexican-Americans suggested at least a
twofold increase in lung cancer risk for the Pro/Pro
homozygotes. Also, an increased risk was observed
for African-American65 and white populations with
the Pro/Pro genotype.36,50 The majority of studies
that associate p53 Pro/Pro genotype with lung cancer
have been reported from Southeast Asia (China,
Taiwan, or Japan). In contrast, we have found an
increased frequency of Arg/Arg genotypes in lung
cancer patients revealing nearly a fivefold increased
risk (p 0.004; OR, 5.13; 95% CI, 1.59 to 17.26)
[Table 1]. This is in agreement with the study of
Papadakis and group,22 who also observed an in-
creased frequency of the Arg/Arg genotype in lung
cancer patients compared to normal control subjects.
The frequency of the Arg/Arg genotype is certainly
higher in lung cancer patients and correlates posi-
tively with various clinicopathologic features. Inter-
estingly, the frequency of Arg/Arg homozygotes also
increased with the increasing severity of the disease.
However, the difference was not found to be statis-
tically significant in all stages. Several authors49,62
reported an increased frequency of Pro/Pro homozy-
gosity in adenocarcinoma of the lung. We observed a
higher frequency of the Arg/Arg allele in both squa-
mous cell carcinoma (52.3%) as well as adenocarci-
noma (33.3%), compared to only 15% in healthy
control subjects (Tables 1, 2). Our observation of
25% and 10% of the Pro/Pro allele in control sub-
jects and cancer patients, respectively, is in good
agreement with the Beckman hypothesis that with
the increasing latitude, the frequency of the Pro/Pro
genotype decreases, and it has been shown to vary
from 63% in African blacks to 17% in Swedish
Saamis. This is suggested to be due to natural
selection through ecological adaptation to ultraviolet
radiation.31
One of the interesting observation was that of the
stage IV lung cancer patients who showed a higher
proportion (60%) of Arg/Pro heterozygosity, and as
high as 77.8% of these stage IV patients showed a
shorter duration of symptoms ( 4 months). This is
indicative of the fact that the patients with the
heterozygous p53 Arg/Pro genotype seem to have a
higher progression rate or aggressive clinical behav-
ior. Since the duration of symptoms is an elusive end
point due to early death or other reasons, further
study with a larger group of patients could establish
if the prevalence of the Arg/Pro genotype can serve
as a significant prognostic/susceptibility marker for
advanced lung cancer patients. Although, no signifi-
cant difference was found between p53 codon 72
polymorphism and different clinicopathologic fea-
tures of lung cancer patients, the homozygous p53
Arg/Arg genotypes, in general, do show an increasing
trend with the increasing severity of the lesions, age,
and pack-years (Table 2). This suggests that a higher
prevalence of arginine homozygosity could be a
genetic risk factor for the development of lung
cancer in India. However, due to low frequency of
HPV, it is difficult to associate p53 Arg homozygosity
with HPV in lung cancer.
Several studies have demonstrated contradictory
results associating either p53 proline or p53 arginine
homozygosity with lung cancer.22,36,49,50,54,64 The dis-
crepancies in the results may be attributed to various
reasons such as selection of patients and control
subjects, variation in laboratory protocols, and geo-
graphic and ethnic background. Fan et al,62 who
demonstrated the association of p53 proline homozy-
gosity with lung cancer, had studied only primary
lung cancer stage I and II patients and excluded
patients of advanced stage, whereas Papadakis and
his group22 studied advanced lung cancer patients
(stage III and IV) and suggested association of p53
Table 4—Frequency of p53 Polymorphism in Lung Cancer: Worldwide Scenario*
Study No. Sample Size Arg/Arg Arg/Pro Pro/Pro Region Source/Year
1 328 148 (45.1) 127 (38.7) 53 (16.2) Saitama, Japan Kawajiri et al,50 1993
2 109 34 (31.2) 54 (49.5) 21 (19.3) Texas Jin et al,65 1995
3 178 76 (42.7) 83 (46.6) 19 (10.7) Chiba, Japan Tagawa et al,54 1998
4 114 39 (34.2) 45 (39.5) 30 (26.3) Taichung, Taiwan Wang et al,36 1999
5 482 212 (44.0) 204 (42.3) 66 (13.7) Massachusetts Fan et al,62 2000
6 334 144 (43.1) 138 (41.3) 52 (15.6) Hawaii Pierce et al,53 2000
7 767 367 (48.0) 299 (39.0) 101 (13.0) Massachusetts Miller et al,66 2002
8 54 27 (50.0) 27 (50.0) 0 (0) Athens, Greece Papadakis et al,22 2002
9 40 19 (47.5) 17 (42.5) 4 (10.0) New Delhi, India This study
*Data are presented as No. (%) unless otherwise indicated.
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arginine homozygosity with lung cancer. Also, in the
present study, the majority (33 of 40 patients, 82.5%)
belonged to stage III and IV, which showed a
preponderance of p53 Arg homozygosity. However,
it is highly intriguing that, although arginine homozy-
gosity has been found to be associated with lung
cancer in the present study, it is neither proline nor
arginine homozygosity but Arg/Pro heterozygosity
that has shown higher incidence in majority of stage
IV patients who showed faster progression to ad-
vanced stage of lung cancer. A similar association of
the Arg/Pro genotype with an increased risk of
cervical cancer has also been reported.67,68 At
present, it is difficult to indicate specific reason(s) or
the biological basis for the increased susceptibility to
progression in Arg/Pro heterozygote individuals.
However, it has been observed that arginine ho-
mozygosity allows certain p53 mutants to form stable
complex with p73 and block its apoptotic ability by
inactivation of p73 protein.69,70 It indicates that the
p53 Arg allele is preferentially retained in Arg/Pro
germline heterozygotes. It is also possible that there
might be some yet unknown mutation in the p53
gene either in the exon or in the intronic region and/
or additional genetic or epigenetic changes in other
gene(s) which may make Arg/Pro heterozygous pa-
tients highly susceptible for an early progression to
invasive cancer. A somewhat similar situation has
been observed in a Southeast Asian population,
where the p53 proline homozygous genotype has
been associated with lung cancer, but a low fre-
quency of another p53 gene polymorphism at intron
3, a 16-bp duplication that offers protection against
lung cancer,51 makes this population more prone to
lung cancer.
In conclusion, our findings suggest no major role
of HPV but a strong association of p53 Arg homozy-
gotes with advanced lung cancer. Nevertheless, the
presence of Arg/Pro heterozygotes may associate
with early progression of the disease possibly due to
additional genetic alteration(s). Therefore, further
studies are required on a larger sample size to
unravel the role of HPV and p53 codon 72 polymor-
phism in the genesis of lung cancer in humans.
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